Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Verastem ( (VSTM) ) has issued an announcement.
On December 29, 2025, Verastem announced it will discontinue the RAMP 203 Phase 1/2 clinical trial in advanced KRAS G12C-mutated non-small cell lung cancer, halting further enrollment while allowing currently enrolled patients to continue treatment at investigators’ discretion. Interim data as of November 26, 2025, showed that doublet and triplet combinations of avutometinib with LUMAKRAS and defactinib produced meaningful response rates and generally manageable safety, but next-generation KRAS G12C inhibitors have raised the efficacy bar, prompting Verastem to reallocate resources toward the clinical development of VS-7375, its oral KRAS G12D (ON/OFF) inhibitor that has shown high response rates in KRAS G12D NSCLC, and to its RAMP 205 pancreatic cancer program, signaling a strategic shift to indications and assets with greater perceived commercial and clinical impact.
The most recent analyst rating on (VSTM) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Verastem stock, see the VSTM Stock Forecast page.
Spark’s Take on VSTM Stock
According to Spark, TipRanks’ AI Analyst, VSTM is a Neutral.
The score is held down primarily by weak financial fundamentals (large operating losses, heavy cash burn, negative equity and higher debt). Technicals also indicate soft momentum with price below key moving averages and negative MACD. Offsetting these, the latest earnings call described strong early commercial traction and advancing trials with runway into 2H 2026, but not enough to outweigh current financial risk.
To see Spark’s full report on VSTM stock, click here.
More about Verastem
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company focused on developing targeted therapies for RAS/MAPK pathway-driven cancers. Its lead products include the AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets), which received U.S. FDA accelerated approval on May 8, 2025, for adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy, and the company is advancing multiple clinical programs in ovarian, pancreatic and lung cancers.
Average Trading Volume: 2,236,805
Technical Sentiment Signal: Sell
Current Market Cap: $584.5M
See more data about VSTM stock on TipRanks’ Stock Analysis page.